Company: DNLI
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001628280-25-056361
Chunk: 42

Company: Denali Therapeutics Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 42
---
 forth in the table above.

The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by us, and proceeds before expenses to us. Such amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares.

|                                                         |     | Per Share |        |     | Per        
 Pre-Funded 
 Warrant    |        |     | Total       
 No Exercise |                |     | Full Exercise |                |
|:--------------------------------------------------------|:----|:----------|-------:|:----|:-----------|-------:|:----|:------------|---------------:|:----|:--------------|---------------:|
| Public offering price                                   |     | $         |  17.50 |     | $          |  17.49 |     | $           | 199,977,135.36 |     | $             | 229,977,122.86 |
| Underwriting discounts and commissions to be paid by us |     | $         |  0.875 |     | $          |  0.875 |     | $           |   9,999,999.63 |     | $             |  11,499,999.00 |
| Proceeds, before expenses, to us                        |     | $         | 16.625 |     | $          | 16.615 |     | $           | 189,977,135.73 |     | $             | 218,477,123.86 |

Shares sold by the underwriters to the public will be offered at the public offering price set forth on the cover of this prospectus supplement. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $0.525 per share from the public offering price. After the initial offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part. The underwriters have not been engaged to act as warrant agent for the pre-funded warrants or to act as underwriter or agent or otherwise participate in the issuance of the shares of our common stock upon the exercise of the pre-funded warrants.

<div align='center'>S-33</div>

We have agreed that, without the prior written consent of Goldman Sachs & Co. LLC, for a period of